1-甲基-4-(4-硝基苯)哌嗪 | 70261-81-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-甲基-4-(4-硝基苯)哌嗪
• 中文别名: 1-甲基-4-(4-硝基苄基)哌嗪
• 英文名称: 1-methyl-4-(4-nitrobenzyl)piperazine
• 英文别名: 4-(4-nitrobenzyl)-1-methylpiperazine；4-methyl-1-(4-nitrobenzyl)piperazine；4-[(4-methyl-piperazine-1-yl)-methyl]-nitrobenzene；1-methyl-4-[(4-nitrophenyl)methyl]piperazine；4-(4-methyl-piperazin-1-yl)-nitrobenzene；1-methyl-4-(4-nitro-benzyl)-piperazine
• CAS: 70261-81-3
• 化学式: C₁₂H₁₇N₃O₂
• mdl: MFCD00976866
• 分子量: 235.286
• InChiKey: TZZWNVPIAQKNTG-UHFFFAOYSA-N

物化性质

• 沸点：
  358.2±27.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Methyl-4-(4-nitrobenzyl)piperazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Methyl-4-(4-nitrobenzyl)piperazine
CAS number: 70261-81-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H17N3O2
Molecular weight: 235.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-4-(4-硝基苯)哌嗪 在 FeO(OH)/C 、 1-羟基苯并三唑 、 一水合肼 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 4-benzamido-N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1H-pyrazole-5-carboxamide
  参考文献：
  名称：

  Novel 1<i>H</i>-Pyrazole-3-carboxamide Derivatives: Synthesis, Anticancer Evaluation and Identification of Their DNA-Binding Interaction

  摘要：

  合成了四种新型 1H-吡唑-3-甲酰胺衍生物，并研究了它们对癌细胞的抗增殖作用、激酶抑制作用，特别是 DNA 结合相互作用，以解释抗肿瘤机制。开发了 DNA 小沟结合模型，并预测了化合物的结合能。与预测一致，在生理条件下通过电子吸收光谱测定了化合物的结合能力，并通过粘度测量进一步验证。一种化合物 5-(3-环丙基脲基)-N-[4-[(4-甲基哌嗪-1-基)甲基]苯基]-1-H-吡唑-3-甲酰胺 (pym-5) 具有最高的 DNA 结合能力亲和力（Kpym-5=1.06×105 M−1）。结果表明，荧光光谱中溴化乙锭-小牛胸腺 DNA (EB-CT-DNA) 复合物的发射强度降低了 50% 以上，表明 pym-5 可以强烈影响 DNA 构象。此外，在 pBR322 DNA 切割测定中，pym-5 对超螺旋质粒 pBR322 DNA 显示出切割活性。我们的研究表明 DNA 可能作为这些吡唑衍生物的潜在靶标。

  DOI：

  10.1248/cpb.c13-00676
• 作为产物：
  描述：

  4-硝基甲苯 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 potassium carbonate 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 15.0h， 生成 1-甲基-4-(4-硝基苯)哌嗪
  参考文献：
  名称：

  抑制剂克服干细胞因子受体KIT中的继发突变。

  摘要：

  在现代癌症治疗中，已证明使用抗受体酪氨酸激酶（RTK）的有机小分子是一种有价值的策略。癌细胞与与RTK连锁的失调的信号通路的关联代表了靶向癌症治疗中的关键要素。酪氨酸激酶肥大/干细胞生长因子受体KIT是临床相关RTK的一个例子。KIT的目标是在胃肠道间质瘤（GIST）和慢性粒细胞性白血病（CML）中进行癌症治疗。但是，在催化域内获得性耐药突变降低了该策略的效力，并且是治疗失败的最常见原因。在这里，我们介绍了新型II型激酶抑制剂的结构化设计和合成，以克服KIT中的这些突变。

  DOI：

  10.1021/acs.jmedchem.7b00841

文献信息

• [EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
  申请人：CEPHALON INC

  公开号：WO2010071885A1

  公开（公告）日：2010-06-24

  The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐形式，其中Q1、Q2、Q3和Q4如本文所定义。式（I）的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• Aminomethylation via Cyclopalladated-Ferrocenylimine-Complexes-Catalyzed Suzuki-Miyaura Coupling of Aryl Halides with Potassium N,N-Dialkylaminomethyltrifluoroborates
  作者：Yangjie Wu、Yusheng Wu、Dapeng Zou、Hongmeng Cui、Lijin Qin、Jingya Li

  DOI：10.1055/s-0030-1259331

  日期：2011.2

  Using cyclopalladated ferrocenylimine complexes (1-3 mol%) as catalysts, the Suzuki-Miyaura coupling of potassium N,N-dialkylaminomethyltrifluoroborates with aryl and heteroaryl halides were carried out in a 10:1 THF-H2O mixture at 80 ˚C in the presence of Cs2CO3 (3.0 equiv) as base, giving the desired cross-coupling products in 14-87% yields. A variety of potassium alkyltrifluoroborates were also examined.

  使用环钯化二茂铁亚胺配合物（1-3摩尔%）作为催化剂，在Cs2CO3（3.0当量）作为碱的存在下，在80 ℃的10:1 THF-H2O混合物中，进行钾N,N-二烷基氨基甲基三氟硼酸盐与芳基和杂芳基卤化物的铃木-宫浦偶联反应，得到了所需的交叉偶联产物，产率为14-87%。还研究了各种烷基三氟硼酸钾。
• Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT
  作者：Helena Kaitsiotou、Marina Keul、Julia Hardick、Thomas Mühlenberg、Julia Ketzer、Christiane Ehrt、Jasmin Krüll、Federico Medda、Oliver Koch、Fabrizio Giordanetto、Sebastian Bauer、Daniel Rauh

  DOI：10.1021/acs.jmedchem.7b00841

  日期：2017.11.9

  In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in targeted cancer therapies. The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clinically relevant RTK. KIT is targeted

  在现代癌症治疗中，已证明使用抗受体酪氨酸激酶（RTK）的有机小分子是一种有价值的策略。癌细胞与与RTK连锁的失调的信号通路的关联代表了靶向癌症治疗中的关键要素。酪氨酸激酶肥大/干细胞生长因子受体KIT是临床相关RTK的一个例子。KIT的目标是在胃肠道间质瘤（GIST）和慢性粒细胞性白血病（CML）中进行癌症治疗。但是，在催化域内获得性耐药突变降低了该策略的效力，并且是治疗失败的最常见原因。在这里，我们介绍了新型II型激酶抑制剂的结构化设计和合成，以克服KIT中的这些突变。
• [EN] BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'URÉE KINASE BICYCLIQUES ET LEURS UTILISATIONS
  申请人：BROAD INST INC

  公开号：WO2018009544A1

  公开（公告）日：2018-01-11

  The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

  本公开提供了公式(I)、(II)和(III)的化合物。所提供的化合物能够结合蛋白激酶（例如，SIK）并可能在调节（例如，抑制）主体或细胞中蛋白激酶（例如，SIK，例如，SIK1、SIK2或SIK3）的活性方面有用。所提供的化合物可能在治疗或预防需要治疗的主体中的疾病（例如，增殖性疾病、肌肉骨骼疾病、遗传性疾病、血液病、神经病、疼痛状况、精神障碍或代谢紊乱）方面有用。还提供了包括或涉及此处描述的化合物的药物组合物、试剂盒、方法和用途。
• Synthesis of new amides of the N-methylpiperazine series
  作者：E. V. Koroleva、K. N. Gusak、Zh. V. Ignatovich、A. L. Ermolinskaya

  DOI：10.1134/s1070428011100198

  日期：2011.10

  erazin-1-ylmethyl)phenyl]benzamides. 4-Methyl-3-nitrophenyl-4-methylpiperazin-1-yl-substituted benzamides were reduced with hydrazine hydrate over Raney nickel to obtain N-(3-amino-4-methylphenyl)-4-(4-methylpiperazin-1-ylmethyl)benzamide as key intermediate in the synthesis of antileukemic agent imatinib and its isomer with alternative position of the amide group, 4-[(3-amino-4-methylphenylamino)

  通过1-甲基哌嗪或3-和4-（4-甲基哌嗪-1-基甲基）苯胺与4-氯苯甲酰氯的反应和4-甲基-3-硝基苯胺与4的反应合成含有N-甲基哌嗪片段的新的羧酸酰胺。-（4-甲基哌嗪-1-基甲基）苯甲酰氯或苯并三唑-1-基4-（4-甲基哌嗪-1-基甲基）苯甲酸酯。4-氯-N- [4-（4-甲基哌嗪-1-基甲基）苯基]苯甲酰胺与咪唑，喹啉-5-胺和2-甲基喹啉-5-胺反应，生成取代的4-氨基-N- [4 -（4-甲基哌嗪-1-基甲基）苯基]苯甲酰胺。用水合肼在阮内镍上还原4-甲基-3-硝基苯基-4-甲基哌嗪-1-基取代的苯甲酰胺，得到N-（3-氨基-4-甲基苯基）-4-（4-甲基哌嗪-1-基甲基）苯甲酰胺是抗白血病药物伊马替尼及其异构体的合成中间体，具有酰胺基的替代位置，4-[（3-氨基-4-甲基苯基氨基）甲基]苯基-（4-甲基哌嗪-1-基）甲酮。